CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Phase 1

Terminated

Conditions: Cholestasis
Pancreatic Neoplasms

Interventions: Drug: nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2014-10-17

Last Posted Date: 2019-11-01

Lead Sponsor: Celgene

Target Recruit Count: 1

Registration Number: NCT02267707

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
🇩🇪
St. Josef-Hospital, Bochum, Germany

and more 3 locations

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: nab-paclitaxel IV
Drug: CC-486
Drug: Duravalumab

First Posted Date: 2014-09-26

Last Posted Date: 2023-09-21

Lead Sponsor: Celgene

Target Recruit Count: 240

Registration Number: NCT02250326

Locations: 🇨🇦
Local Institution - 641, Montreal, Quebec, Canada
🇬🇧
Local Institution - 636, Manchester, United Kingdom
🇮🇹
Local Institution - 673, Bologna, Italy

and more 31 locations

Radiolabeled Study of CC-122 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-122

First Posted Date: 2014-09-09

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 6

Registration Number: NCT02234999

Locations: 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Phase 1

Completed

Conditions: Hodgkin's Lymphoma
Multiple Myeloma
Melanoma
Non-Hodgkin's Lymphoma
Leukemia
Neoplasms
Small Cell Lung Cancer
Hematological Neoplasms
Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: CC-486
Drug: Vidaza

First Posted Date: 2014-08-22

Last Posted Date: 2020-05-12

Lead Sponsor: Celgene

Target Recruit Count: 89

Registration Number: NCT02223052

Locations: 🇺🇸
The Methodist Hospital Research Institute l, Houston, Texas, United States
🇺🇸
Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 7 locations

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Phase 2

Withdrawn

Conditions: Sarcoidosis

Interventions: Drug: CC-220 0.3 mg Daily
Drug: Placebo
Drug: CC-220 0.6mg Daily

First Posted Date: 2014-07-16

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Registration Number: NCT02192489

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215 in combination with pomalidomide and dexamethasone

First Posted Date: 2014-07-14

Last Posted Date: 2019-11-21

Lead Sponsor: Celgene

Target Recruit Count: 16

Registration Number: NCT02189343

Locations: 🇺🇸
CTRC at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: CC-220
Drug: Placebo

First Posted Date: 2014-07-09

Last Posted Date: 2020-03-19

Lead Sponsor: Celgene

Target Recruit Count: 42

Registration Number: NCT02185040

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC, Paradise Valley, Arizona, United States
🇺🇸
UCSD Center for Innovative Therapy, La Jolla, California, United States

and more 32 locations

Food Effect and CYP1A2 Induction Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Pomalidomide
Other: Caffeine
Other: Tobacco

First Posted Date: 2014-06-20

Last Posted Date: 2018-11-15

Lead Sponsor: Celgene

Target Recruit Count: 55

Registration Number: NCT02168205

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Completed

Conditions: Multiple Myeloma

Interventions: Drug: IMNOVID

First Posted Date: 2014-06-17

Last Posted Date: 2022-10-20

Lead Sponsor: Celgene

Target Recruit Count: 775

Registration Number: NCT02164955

Locations: 🇧🇪
Centre Hospitalier Peltzer-La Tourelle, Verviers, Rue Du Parc 29, Belgium
🇧🇪
Clinique Saint-Pierre, Ottignies, Belgium
🇬🇧
Broomfield Hospital, Broomfield,Chelmsford, Essex, United Kingdom

and more 119 locations

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

Completed

Conditions: Multiple Myeloma
Leuklemia, Lymphocytic, Chronic
Myelodysplastic Syndromes
Leukemia Myeloid Acute

Interventions: Other: Geriatric Assessment of Health Status Scale administration

First Posted Date: 2014-06-16

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 363

Registration Number: NCT02164071

Locations: 🇪🇸
Hospital Txagorritxu, Vitoria, Alava, Spain
🇪🇸
Hospital Parc Tauli, Sabadell, Barcelona, Spain
🇪🇸
Hospital de Donostia, San Sebastian, Guipuzcoa, Spain

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy